Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Science Board To Review Comparative Effectiveness, Pharmacovigilance, Nanotech

This article was originally published in The Pink Sheet Daily

Executive Summary

The May 20 meeting follows a recent reorganization of the safety functions in the Center for Drug Evaluation and Research.

You may also be interested in...



FDA’s Lead-In-Lipstick Testing Completed, Cosmetics Director Says

Among 2010 accomplishments, FDA’s Office of Cosmetics and Colors completed investigations into lead in lipstick and asbestos in talc, Director Dr. Linda Katz said during the Personal Care Products Council’s Regulatory Science Summit April 13 in Washington.

FDA Funds To Rise Despite Widespread Reductions In 2011 Appropriations

Despite a $37.6 billion overall cut in federal government domestic spending, a compromise fiscal 2011 funding agreement gives FDA about $107 million more dollars, totaling about $2.46 billion, compared to 2010.

CDER Reorganization Creates Drug Safety “Super-Office”; Management Support Is Goal

Elevation of the Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology to a “super-office” is expected to provide greater management support to the drug safety unit’s growing number of staff and responsibilities.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072304

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel